Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 3996-4002

  Tessitore, Nicola ^a   Girelli, Domenico ^b   Campostrini, Natascia ^b   Bedogna, Valeria ^a   Pietro Solero, Giovanni ^b   Castagna, Annalisa ^b   Melilli, Edoardo ^a   Mantovani, William ^c   De Matteis, Giovanna ^b   Olivieri, Oliviero ^b   Poli, Albino ^c   Lupo, Antonio ^a  

^a Division of Nephrology   (Italy)

^b Hematology and Molecular Biology Laboratory   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

diagnostic accuracy; erythropoiesis stimulating agents; haemodialysis; hepcidin; iron deficiency

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 20; HEPCIDIN 25; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERYTHROPOIESIS; FEMALE; GENOTYPE; HEMODIALYSIS; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETICULOCYTE; STATISTICAL SIGNIFICANCE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; FEMALE; HEMATINICS; HEMOGLOBINS; HOMEOSTASIS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78649520453     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq321     Document Type: Article

References (37)

1. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
2. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614
3. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17: 53-59
4. Macdougall IC, Tucker B, Thompson J et al. A randomised controlled trial of iron supplementation in patients treated with erythro-poietin. Kidney Int 1996; 50: 1694-1699
5. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
6. Singh AK, Coyne DW, Shapiro Wet al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
7. Besarab A, Frinak S, Yee E. An indistinct balance: the safety and efficacy of parenteral iron. J Am Soc Nephrol 1999; 10: 2029-2043
8. Bishu K, Agarwall R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1: S19-S23
9. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1: S4-S8
10. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
11. Ludwiczek S, Aigner E, Theurl I et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148-4154
12. Bovy C, Tsobo C, Crapanzano L et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56: 1113-1119
13. Tarng DC, Huang TP. Determinants of circulating soluble transfer-rin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1063-1069
14. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400
15. Nicolas G, Viatte L, Bennoun N et al. Hepcidin, a new iron regulatory peptide. Blood Cell Mol Dis 2002; 29: 327-335
16. Swinkels DW, Wetzels JFM. Hepcidin: a new tool in the management of anemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008; 23: 2450-2453
17. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009; 4: 1384-1387
18. Zaritsky J, Young B, Gales B et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; doi: 10.2215/CJN.08161109
19. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hep-cidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387
20. Kato A, Tsuji T, Luo J et al. Association of prohepcidin and hep-cidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121
21. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981
22. Zaritsky J, Young B, Wang H et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056
23. Valenti L, Girelli D, Valenti GF et al. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1331-1337
24. Weiss G, Theurl I, Eder S et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effect of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890
25. Peters HPE, Laarakkers CMM, Swinkels DWet al. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010; 25: 848-853
26. Costa E, Swinkels DW, Laarakkers CM et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009; 122: 226-229
27. Cavill I, Macdougall IC. Erythropoiesis and iron supply in patients treated with erythropoietin. Erythropoiesis 1992; 3: 50-55
28. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
29. Bovy C, Gothot A, Delanaye P et al. Mature erythrocyte parameters as new markers of functional iron deficiency in hemodialysis: sensitivity and specificity. Nephrol Dial Transplant 2007; 22: 1156-1162
30. Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am J Kidney Dis 2006; 47: 1036-1044
31. Oberkanins C, Moritz A, de Villiers NPet al. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000; 4: 121-124
32. Bozzini C, Campostrini N, Trombini P et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis 2008; 40: 347-352
33. Swinkels DW, Girelli D, Laarakkers C et al. AdVances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 2008; 3: e2706
34. Besarab A, Amin N, Ahsan M et al. Optimization of Epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
35. Malyszko J, Malyszko JC, Mysliwiec M. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy. Kidney Blood Press Res 2009; 32: 235-238
36. De Domenico I, Nemeth E, Nelson JM et al. The hepcidin-binding site on ferroportin is evolutionary conserved. Cell Metab 2008; 8: 146-156
37. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343